BPC-157 and TB-500 — What the Published Research Examines

BPC-157 and TB-500 are two of the most studied peptides in the current research literature. Both have been the subject of a significant volume of preclinical investigation, and both appear in a wide range of academic publications exploring cellular and tissue-level mechanisms.

This article summarises what the published research has examined — without making claims about human outcomes or therapeutic applications.

BPC-157 — Background and Research Context

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein found in gastric juice. It was first identified and studied by researchers at the University of Zagreb, and has since become one of the more extensively published research peptides in the preclinical literature.

The majority of BPC-157 research has been conducted in rodent models. Published studies have explored its effects on a range of biological systems, with particular focus on:

• Gastrointestinal tissue at a cellular level
• Tendon and ligament tissue in animal injury models
• Angiogenesis (the formation of new blood vessels) in laboratory settings
• Nitric oxide system modulation in preclinical models
• Neurological signalling pathways in animal studies

A 2018 review published in Current Neuropharmacology examined neurological research around BPC-157, noting its interaction with dopamine and serotonin systems in animal models. Research published in the Journal of Physiology and Pharmacology has explored its effects on gastrointestinal tissue in preclinical settings.

It is important to note that human clinical trial data for BPC-157 remains very limited. The existing body of research is predominantly preclinical, and conclusions drawn from animal or in vitro studies cannot be directly extrapolated to human outcomes.

TB-500 — Background and Research Context

TB-500 is a synthetic version of Thymosin Beta-4 (Tb4), a naturally occurring peptide found in virtually all human and animal cells. Thymosin Beta-4 plays a role in actin regulation — a process central to cell structure and movement — and has been studied extensively in wound healing and tissue repair research.

The academic literature on Thymosin Beta-4 and its synthetic analogue TB-500 has examined:

• Actin polymerisation and cellular migration in laboratory models
• Wound healing mechanisms in animal studies
• Cardiac tissue research in preclinical models
• Anti-inflammatory pathway modulation in laboratory settings

Research published in the Annals of the New York Academy of Sciences has explored Thymosin Beta-4's role in tissue repair mechanisms. Studies in the Journal of Molecular Medicine have examined its interaction with cellular signalling pathways in preclinical models.

As with BPC-157, the human clinical trial literature for TB-500 is limited. Existing research is largely preclinical and should be understood within that context.

Research Considerations

Both compounds are of ongoing academic interest due to the specificity of their proposed mechanisms and the volume of preclinical data that has accumulated over recent decades.

Researchers working with these compounds should:

• Source only from suppliers with verifiable third-party testing and COA documentation
• Review the primary literature directly rather than relying on secondary sources
• Maintain accurate records of research protocols and compound handling
• Operate within the UK MHRA research compounds framework at all times

At PerformanceLabs UK, both BPC-157 and TB-500 are available as third-party tested research compounds with full COA documentation. They are supplied strictly for research use only.